RECURSION PHARMACEUTICALS, INC.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage biotechnology company operating at the intersection of artificial intelligence and drug discovery. The company's website is www.recursion.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What RECURSION PHARMACEUTICALS, INC. does
In the company’s own words
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage biotechnology company operating at the intersection of artificial intelligence and drug discovery. The company's website is www.recursion.com.
Recursion has developed an integrated, AI-native operating system called the Recursion OS that spans the entire drug discovery and development value chain from biological research through clinical trials. The platform combines proprietary multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development to identify and advance novel therapeutic candidates. The company's approach aims to reshape the traditional drug discovery funnel by leveraging advanced computational tools to identify candidates with the highest probability of success earlier in development, thereby reducing timelines and capital requirements compared to conventional methods.
The company maintains a portfolio combining wholly owned programs and strategic partnerships with major pharmaceutical companies. Recursion's internal pipeline includes five clinical-stage programs and multiple preclinical programs focused on oncology and rare diseases. The company has established significant partnerships with Roche and Genentech, Sanofi, Bayer, and Merck KGaA, generating over five hundred million dollars in upfront and progress-based milestone payments to date, with potential for additional payments exceeding twenty billion dollars before royalties.
Recursion's core capabilities rest on three foundational elements: proprietary data generated through automated high-throughput laboratories capable of running over two million experiments weekly, purpose-built AI models and compute infrastructure including the BioHive-2 supercomputer, and integrated teams of scientists and engineers fluent in both life sciences and technology. The company's platform generates value through advancing differentiated investigational medicines while building pipelines for pharmaceutical partners across oncology, neuroscience, immunology, and other therapeutic areas with significant unmet medical needs.
The company is a non-accelerated filer with the Securities and Exchange Commission and has identified material weaknesses in internal control over financial reporting. Recursion operates as a clinical-stage entity without approved commercial products or product revenue, relying on partnership payments and capital raises to fund operations.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SALT LAKE CITY, UT
- Fiscal year end
- December
- CIK
- 1601830
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns RECURSION PHARMACEUTICALS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · RECURSION PHARMACEUTICALS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do RECURSION PHARMACEUTICALS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of RECURSION PHARMACEUTICALS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in RECURSION PHARMACEUTICALS, INC.'s last four quarterly filings that the numbers alone won't show?”